THRD vs. KRRO, ALT, FULC, NGNE, LRMR, KALV, TVTX, ABUS, ANRO, and ANNX
Should you be buying TF Financial stock or one of its competitors? The main competitors of TF Financial include Korro Bio (KRRO), Altimmune (ALT), Fulcrum Therapeutics (FULC), Neurogene (NGNE), Larimar Therapeutics (LRMR), KalVista Pharmaceuticals (KALV), Travere Therapeutics (TVTX), Arbutus Biopharma (ABUS), Alto Neuroscience (ANRO), and Annexon (ANNX). These companies are all part of the "pharmaceutical preparations" industry.
Korro Bio (NASDAQ:KRRO) and TF Financial (NASDAQ:THRD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, community ranking and media sentiment.
TF Financial received 49 more outperform votes than Korro Bio when rated by MarketBeat users. However, 100.00% of users gave Korro Bio an outperform vote while only 66.67% of users gave TF Financial an outperform vote.
Korro Bio currently has a consensus target price of $126.25, indicating a potential upside of 137.85%. TF Financial has a consensus target price of $7.00, indicating a potential downside of 40.48%. Given TF Financial's stronger consensus rating and higher probable upside, research analysts clearly believe Korro Bio is more favorable than TF Financial.
Korro Bio's return on equity of -6.22% beat TF Financial's return on equity.
TF Financial has lower revenue, but higher earnings than Korro Bio. TF Financial is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.
In the previous week, TF Financial had 6 more articles in the media than Korro Bio. MarketBeat recorded 6 mentions for TF Financial and 0 mentions for Korro Bio. TF Financial's average media sentiment score of 1.05 beat Korro Bio's score of 0.00 indicating that Korro Bio is being referred to more favorably in the media.
Korro Bio has a beta of 2.28, meaning that its stock price is 128% more volatile than the S&P 500. Comparatively, TF Financial has a beta of 2.86, meaning that its stock price is 186% more volatile than the S&P 500.
13.2% of Korro Bio shares are owned by institutional investors. Comparatively, 94.0% of TF Financial shares are owned by institutional investors. 16.8% of Korro Bio shares are owned by company insiders. Comparatively, 5.9% of TF Financial shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Korro Bio and TF Financial tied by winning 8 of the 16 factors compared between the two stocks.
Get TF Financial News Delivered to You Automatically
Sign up to receive the latest news and ratings for THRD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding THRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TF Financial Competitors List
Related Companies and Tools
